Virax Biolabs Group Ltd 6-K, filed Sep 12, 2022
Virax Biolabs Group Ltd (VRAX)
About this 6-K
Virax Biolabs Group Ltd filed this 6-K on September 12, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission File Number: 001-41440
Virax Biolabs Group Limited
(Registrant’s Name)
30 Broadwick Street
London, W1F 8LX
United Kingdom
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
When used in this Current Report on Form 8-K, unless otherwise indicated, the terms “the Company,” “Virax,” “we,” “us” and “our” refer to Virax Biolabs Group Limited. and its subsidiaries.
Item 7.01 Regulation FD Disclosure.
On September 12, 2022, Virax Biolabs Group Limited issued a press release announcing that the Company will be presenting at the H.C. Wainwright Annual Global Investment Conference from September 12 - 14, 2022 at the Lotte New York Palace Hotel, New York, NY, and the pre-recorded and on-demand presentation is now available.
A copy of the press release dated September 12, 2022 is included as Exhibit 99.1 to this report.
Item 9.01 Financial Statements and Exhibits.
|
|
|
|
(d) |
Exhibits |
|
|
|
Exhibit No |
|
Description |
|
|
|
|
||
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
VIRAX BIOLABS GROUP LIMITED |
|
|
|
|
Date: |
September 12, 2022 |
By: |
/s/ Jason Davis |
|
|
|
Jason Davis, Chief Financial Officer |
Virax BioLabs Presents at H.C. Wainwright’s 24th Annual Global Investment Conference
LONDON, Sep. 12, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Chairman of the Board and Chief Executive Officer, James Foster is presenting at H.C. Wainwright’s 24th Annual Global Investment Conference, held in New York, NY and that the pre-recorded and on-demand presentation is now available.
Session details are as follows:
Date: September 12 – 14, 2022 at Lotte New York Palace Hotel, New York, NY
Title: Virax BioLabs Company Presentation
Virax Participant: James Foster, Chairman and Chief Executive Officer
Presentation Link: https://journey.ct.events/view/5b9cade7-f8ea-41c8-b7c6-ff3e1f490fab
Virax management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting from Maxim Jacobs, CFA at Maxim.Jacobs@russopartnersllc.com
About Virax Biolabs Group Limited
Founded in 2013, Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.
Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus. For more information, please visit www.viraxbiolabs.com.
Safe Harbor Statement
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Company Contact:
Virax Biolabs Group Limited
Phone: +44 020 7788 7414
Email: info@viraxbiolabs.com
Investor Relations Contact:
Russo Partners, LLC
Maxim Jacobs, CFA
(646) 942-5591
Email: Maxim.Jacobs@russopartnersllc.com
SOURCE Virax Biolabs